American Bio Medica to Supply its Rapid Drug Screen(R) to Oil Industry Client.

KINDERHOOK, N.Y. -- American Bio Medica Corporation (NASDAQ:ABMC) today announced that an oil field services company has selected ABMC to be its provider of point of collection drug testing devices and support services. The client has requested that its identity not be disclosed. The client will be using ABMC's Rapid Drug Screen drug test devices along with its Rapid Reader(TM) drug screen interpretation and data management system, to screen its employees for illicit drug use. They currently employ thousands of people worldwide and intend to perform random, suspicion, and post accident drug testing. E[acute accent]ABMC Chief Executive Officer Stan Cipkowski stated, "The fact that this premier company has chosen ABMC to be its supplier of drug testing devices is a credit to the accuracy, reliability and cost effectiveness of our products. They join our growing customer base of global companies that have chosen ABMC's point of collection tests because they are less expensive and faster than traditional laboratory testing as well consistently accurate and easy to use. We expect this trend of major companies converting to ABMC products to continue."

E[acute accent]About American Bio Medica Corporation

E[acute accent]American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen, Rapid One(R), Rapid TEC(R), RDS(R) InCup(TM) and Rapid TOX(TM) products test for the presence or absence of drugs of abuse in urine, while OralStat tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

E[acute accent]This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2004, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares